Articles tagged with Melanoma Cells
Scientists discover endothelial cells have higher levels of receptors for endostatin, which protects melanoma cells from angiogenesis inhibitors. This finding may lead to new cancer therapies targeting both angiogenesis and tumor cell vasculogenic mimicry.
Researchers successfully cloned mice from malignant cancer cells using nuclear transfer. The study reveals that the epigenetic elements of cancer can be reversed, whereas genetic mutations are not.
Researchers discovered a synthetic peptide that mimics a protein linkage crucial for melanoma cell migration and angiogenesis. The peptide inhibits this interaction, significantly deterring tumor cell growth and formation of new blood vessels.
Researchers have identified SSX-2, a promising target for cancer vaccines, and found that patients mount their own immunological responses against cancer cells expressing the protein. A new early-phase clinical trial is underway to assess the safety and efficacy of an SSX-2-based vaccine.
A phase II trial of a melanoma vaccine showed promising results, with nearly half of patients living at least five years after receiving the treatment. The vaccine's effectiveness was influenced by the dosing schedule and immune response, highlighting the importance of personalized medicine in cancer treatment.
Sunbeds' tanning properties come with a high risk of skin damage, including DNA mutations associated with malignant melanoma. Experts recommend restricting sunbed use to those over 18 years old and accelerate skin aging.
A new vaccine has shown promise in stimulating a powerful immune response against melanoma tumors, with 10 patients still alive three years after treatment and no signs of disease in four cases. The vaccine, made using a weakened cold virus, was safe and relatively easy to produce, with minimal side effects.
A new study suggests that PTEN dysfunction is responsible for 30-60% of melanomas and offers a potential therapeutic approach to kill cancer cells. The introduction of PTEN into melanoma cells could be a useful treatment option, but the cancer cells may eventually learn to evade this approach.
Researchers have discovered a second mechanism by which LPA promotes ovarian tumor growth through increased cyclin D1 protein levels. Additionally, the identification of PEP, a peptide fragment with vasopermeability activity, may help reduce toxicity in cancer immunotherapy. A new study also suggests that p16 inhibitors play a role in ...
A Rutgers researcher has discovered a gene that causes melanoma by expressing differently in skin cells compared to brain cells. The finding provides new insights into the disease's development and could lead to more targeted treatments.
A phase I clinical trial found that antibody therapy increased the effectiveness of cancer vaccines in patients with metastatic melanoma and ovarian cancer. The treatment, which blocks CTLA-4, elicited a potent immune response and killed cancer cells.
A phase I clinical trial of cytotoxic T-lymphocyte-associated antigen 4 blockade therapy has shown promising results in boosting the immune system against cancer. The treatment enhanced the anti-tumor activity of certain vaccines and improved responses in patients with melanoma and ovarian cancer.
Researchers have discovered a specific molecular pathway within cells that becomes mutated by ultraviolet light exposure, accelerating melanoma development. The study's findings suggest a rational method for risk stratification and screening of atypical skin moles, which could help identify patients with high-risk profiles.
Researchers found that UV radiation triggers melanoma formation by dismantling the Rb pathway in skin pigment-producing cells. This discovery suggests a new way to distinguish cancerous moles from non-cancerous ones, potentially saving lives.
A clinical trial using lab-grown T cell clones has shown promise in shrinking melanoma tumors. In the study, five patients saw their tumors stop growing for up to a year, while three experienced tumor shrinkage.
A new experimental technique called adoptive transfer has shown significant promise in treating metastatic melanoma by replacing immune cells with those specifically designed to destroy tumors. The treatment resulted in at least 50% tumor shrinkage in six patients, with no growth or appearance of new tumors.
A new therapy boosts the immune system's targeted assault on tumors, shrinking melanoma in human patients. The approach involved suppressing the patients' immune systems to make room for new cells that attacked and killed tumor cells.
Researchers at the Weizmann Institute found that Nr-CAM expression is associated with human melanoma and colon cancer development, contributing to tumorigenesis. The gene's role in cell proliferation and tumor formation was confirmed through DNA microarray analysis and animal studies.
A recent study found that 31.7 percent of Americans had been sunburned within the previous 12 months, with white men being the most likely to experience sunburn at 44 percent. Higher education and income levels were also associated with higher rates of sunburn, highlighting a concerning trend among young adults.
Researchers found that melanocytes, pigment-producing skin cells, are resistant to chemotherapy and radiation due to a protective mechanism involving the MITF gene. This mechanism allows them to survive solar radiation, making melanoma treatment challenging.
The Rush University Medical Center has opened a new tissue and cell lab to develop clinical-grade human cellular components for treating certain cancers. The facility will utilize immunotherapy, using the patient's own cells to target cancerous cells.
Researchers discovered that COX-2 inhibition can prevent Barrett's esophageal cell proliferation and that p16 mutations may impair melanocyte senescence. Additionally, a common polymorphism in the GH1 gene may be associated with a decreased risk of colorectal cancer.
Introgen's gene drug demonstrates tumor growth control by targeting the mda-7 gene, a key tumor suppressor. The study shows that replacing the mda-7 function in cancer cells can stop tumor growth and is promising for treating advanced melanoma.
A genetic mutation known as Id1 may help detect melanoma early, when it's still curable. High levels of Id1 are found only in the first stages of melanoma, making it a potential diagnostic marker.
Researchers infected mouse melanocytes with a retrovirus and observed transformed cells behaving like melanoma cells. The study aims to understand the molecular mechanisms underlying melanoma in people by identifying cellular genes disturbed by the virus.